PRAKASH MASAND to Double-Blind Method
This is a "connection" page, showing publications PRAKASH MASAND has written about Double-Blind Method.
Connection Strength
0.329
-
A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. Psychosomatics. 2009 Jan-Feb; 50(1):78-86.
Score: 0.059
-
Criteria for defining symptomatic and sustained remission in bipolar I disorder: a post-hoc analysis of a 26-week aripiprazole study (study CN138-010). Psychopharmacol Bull. 2008; 41(2):12-23.
Score: 0.055
-
Cariprazine for the treatment of bipolar mania with mixed features: A post hoc pooled analysis of 3 trials. J Affect Disord. 2019 10 01; 257:600-606.
Score: 0.031
-
Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease. Hepatology. 2018 03; 67(3):858-872.
Score: 0.028
-
Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison. Int Clin Psychopharmacol. 2017 09; 32(5):235-248.
Score: 0.027
-
A 13-week, randomized double-blind, placebo-controlled, cross-over trial of ziprasidone in bipolar spectrum disorder. J Clin Psychopharmacol. 2015 Jun; 35(3):319-23.
Score: 0.023
-
A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. PLoS One. 2012; 7(4):e34757.
Score: 0.019
-
History of depressive and/or anxiety disorders as a predictor of treatment response: a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Aug 31; 33(6):996-1002.
Score: 0.015
-
Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression: results from a 4-week, double-blind, placebo-controlled trial. Clin Neuropharmacol. 2009 Mar-Apr; 32(2):85-8.
Score: 0.015
-
Childhood abuse and treatment response in patients with irritable bowel syndrome: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. J Clin Pharm Ther. 2009 Feb; 34(1):79-88.
Score: 0.015
-
History of early abuse as a predictor of treatment response in patients with fibromyalgia: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. World J Biol Psychiatry. 2009; 10(4 Pt 2):435-41.
Score: 0.015
-
A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. Am J Med. 2007 May; 120(5):448-54.
Score: 0.013
-
A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol. 2006 Dec; 26(6):653-6.
Score: 0.013